Gene variant | No. of sources | PD with gene variant/controls (n) | Main effect | Heterogeneity | ||
---|---|---|---|---|---|---|
OR or SMD (95% CI)* | P value | I2 statistic (%) | P value | |||
RBD in PD patients with/without gene variants | ||||||
GBA | 7 | 382/2248 | OR: 1.82 (1.21–2.74) | 0.004 | 55.8 | 0.035 |
E326K&T369M | 2 | 125/1533 | OR: 1.43 (0.98–2.07) | 0.062 | 83.4 | 0.014 |
N370S | 2 | 86/414 | OR: 1.64 (1.03–2.61) | 0.039 | 0.0 | 0.396 |
L444P | 2 | 70/125 | OR: 2.02 (1.08–3.75) | 0.021 | 37.9 | 0.204 |
GBA | 7 | 478/2149 | SMD: 0.33 (0.21–0.45) | 0.000 | 0.0 | 0.581 |
N370S | 4 | 304/564 | SMD: 0.24 (0.09–0.39) | 0.002 | 0.0 | 0.919 |
LRRK2 | 13 | 969/3017 | OR: 0.69 (0.48–1.00) | 0.051 | 71.7 | 0.000 |
G2019S | 8 | 685/1191 | OR: 0.49 (0.39–0.61) | 0.000 | 0.0 | 0.639 |
G2385R | 4 | 266/1450 | OR: 1.53 (0.75–3.13) | 0.244 | 75.5 | 0.007 |
LRRK2 | 7 | 512/2858 | SMD: − 0.06 (− 0.32 to 0.19) | 0.628 | 78.6 | 0.000 |
G2019S | 4 | 347/555 | SMD: − 0.33 (− 0.47 to − 0.20) | 0.000 | 0.0 | 0.596 |
G2385R | 2 | 155 / 759 | SMD: 0.21 (− 0.12 to 0.53) | 0.218 | 71.1 | 0.063 |
PRKN | 5 | 122/337 | OR: 0.74 (0.29–1.86) | 0.519 | 60.9 | 0.037 |
PRKN | 2 | 107/1568 | SMD: − 0.17 (− 0.37 to 0.04) | 0.109 | 49.1 | 0.161 |
RBD in asymptomatic patients with gene variants and HC | ||||||
GBA | 4 | 261/370 | OR: 1.04 (0.68–1.59) | 0.861 | 0.0 | 0.920 |
GBA | 2 | 135/81 | OR: 0.22 (− 0.08 to 0.52) | 0.158 | 0.0 | 0.333 |
GBA (baseline) | 2 | 43/38 | SMD: − 0.26 (− 0.69 to 0.18) | 0.252 | 0.0 | 0.922 |
GBA (follow-up) | 2 | 43/38 | SMD: 0.63 (0.18–1.08) | 0.006 | 0.0 | 0.874 |
LRRK2 | 6 | 615/610 | OR: 0.89 (0.52–1.52) | 0.659 | 53.0 | 0.059 |
G2019S | 5 | 551/562 | OR: 0.81 (0.59–1.11) | 0.195 | 44.6 | 0.124 |
LRRK2 | 6 | 457/389 | SMD: 0.08 (− 0.25 to 0.41) | 0.636 | 79.3 | 0.000 |
EDS in PD patients with/without gene variants | ||||||
GBA | 2 | 136/1786 | OR: 0.02 (− 0.16 to 0.20) | 0.832 | 0.0 | 0.437 |
LRRK2 | 5 | 289/1269 | OR: 1.29 (0.59–2.82) | 0.530 | 65.4 | 0.021 |
G2019S | 3 | 111/89 | OR: 2.49 (0.92–6.72) | 0.073 | 37.2 | 0.204 |
G2385R | 2 | 178/1180 | OR: 0.79 (0.57–1.09) | 0.152 | 0.0 | 0.427 |
LRRK2 | 7 | 379/2628 | SMD: 0.05 (− 0.07 to 0.17) | 0.457 | 19.0 | 0.284 |
G2019S | 5 | 290/550 | SMD: 0.05 (− 0.10 to 0.19) | 0.0 | 0.689 | |
PRKN | 2 | 30/91 | OR: 0.21 (0.04–1.23) | 0.084 | 0.0 | 0.424 |
PRKN | 4 | 171/1787 | SMD: 0.11 (− 0.3 to 0.53) | 0.601 | 75.9 | 0.006 |
EDS in asymptomatic patients with gene variants and HC | ||||||
LRRK2 | 4 | 398/320 | OR: 1.06 (0.68–1.65) | 0.811 | 0.0 | 0.446 |
LRRK2 | 4 | 251/227 | SMD: − 0.10 (− 0.43 to 0.24) | 0.574 | 57.8 | 0.068 |
RLS in PD patients with/without gene variants | ||||||
LRRK2 | 3 | 276/1199 | OR: 0.81 (0.60–1.11) | 0.186 | 0.0 | 0.918 |
G2019S | 2 | 113/137 | OR: 0.78 (0.36–1.69) | 0.525 | 0.0 | 0.692 |
PRKN | 3 | 41/102 | OR: 1.01 (0.08–13.22) | 0.995 | 74.6 | 0.020 |
PDSS score in PD patients with/without gene variants | ||||||
LRRK2 | 3 | 67/170 | SMD: 0.12 (− 0.20 to 0.43) | 0.463 | 16.7 | 0.301 |
G2019S | 2 | 51/52 | SMD: 0.19 (− 0.20 to 0.58) | 0.336 | 50.2 | 0.156 |